𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of cell type in bone healing mediated by ex vivo gene therapy

✍ Scribed by Tim Rose; Hairong Peng; Hsain-Chung Shen; Arvydas Usas; Ryosuke Kuroda; Helmut Lill; FreddieH. Fu; Johnny Huard


Publisher
Springer
Year
2003
Tongue
English
Weight
440 KB
Volume
388
Category
Article
ISSN
1435-2451

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Angiogenesis and osteogenesis enhanced b
✍ Dan Qu; Jihua Li; Yubao Li; Ying Gao; Yi Zuo; Yuchun Hsu; Jing Hu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 798 KB

## Abstract Reconstruction of bone defects by tissue engineered substitutes requires coordinated coupling between osteogenesis and angiogenesis. Basic fibroblast growth factor (bFGF or FGF‐2) is a protein which acts actively in osteogenesis and angiogenesis during skeletal healing and development.

In situ generation of pseudotyped retrov
✍ Takashi Okada; Natasha J. Caplen; W. Jay Ramsey; Masafumi Onodera; Kuniko Shimaz 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB

## Abstract ## Background Hybrid adeno‐retroviral vector systems utilize the high efficiency of adenovirus transduction to direct the __in situ__ production of retroviral progeny. In this study, we show that a single‐step transduction of glioma cells with trans‐complementing hybrid adeno‐retrovira

Anti IL-17A therapy inhibits bone loss i
✍ Karin Zwerina; Marije Koenders; Axel Hueber; Renoud J. Marijnissen; Wolfgang Bau 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB

## Abstract Tumour necrosis factor alpha (TNF‐α) is a major inducer for inflammation and bone loss. Here, we investigated whether interleukin (IL)‐17 plays a role in TNF‐α‐mediated inflammation and bone resorption. Human TNF‐α transgenic (hTNFtg) mice were treated with a neutralizing anti‐IL‐17A an

Tissue-specific growth suppression and c
✍ G W Xu; Z T Sun; K Forrester; X W Wang; J Coursen; C C Harris 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 646 KB

HCC patients are generally resistant to chemotherapy, Selective expression of cytotoxic gene products in tuwhich, in some cases, may be the result of a loss of function mor cells is one of the goals of gene therapy for treating mutation in the p53 gene. cancer. We are developing such a strategy for